Vir Biotechnology, INC 8-K filings

Vir Biotechnology announced the departure of its Chief Financial Officer, Jason O'Byrne, effective August 3, 2026, with Brent Sabatini appointed as interim principal financial officer.

Vir Biotechnology has increased its board size to eight members and appointed Timothy Coughlin as a new director and Audit Committee Chair.

Vir Biotechnology reports the resignation of director Saira Ramasastry and the results of its 2026 Annual Meeting.

Vir Biotechnology announced first quarter 2026 financial results, highlighting the closing of its global strategic collaboration with Astellas for VIR-5500 and positive data updates for its chronic hepatitis delta program.

Vir Biotechnology announced that its Executive Vice President and Chief Medical Officer, Mark Eisner, MD, MPH, will be stepping down from his role effective April 24, 2026.

Vir Biotechnology's CEO, Marianne De Backer, has been appointed to the additional role of President, consolidating leadership.

Vir Biotechnology, Inc. successfully closed its public offering, raising approximately $172.5 million in gross proceeds from the sale of over 20 million shares.

Vir Biotechnology, Inc. announced an underwriting agreement for a public offering of 17.6 million common shares at $8.50 each, aiming to raise approximately $141.1 million in net proceeds.

Astellas Pharma and Vir Biotechnology announce a global strategic collaboration to co-develop and co-commercialize VIR-5500, a PSMA-targeting T-cell engager for prostate cancer, with Vir receiving $335 million upfront and near-term payments.

Vir Biotechnology reports strong Phase 2 data for its chronic hepatitis delta combination therapy, extends cash runway into Q4 2027, and provides updates on its oncology pipeline.

Vir Biotechnology has granted Norgine Pharma UK an exclusive license for commercial rights to its investigational chronic hepatitis delta treatment in Europe, Australia, and New Zealand, securing an initial EUR 55 million and up to EUR 495 million in milestones.

Vir Biotechnology announced its third quarter 2025 financial results and provided updates on its chronic hepatitis delta and solid tumor clinical programs, highlighting strong clinical execution and a robust financial position.

Vir Biotechnology reports second quarter 2025 financial results, highlighting progress in its chronic hepatitis delta and oncology pipelines, supported by a strong cash position and extended runway.

Vir Biotechnology announced the dosing of the first patient in its Phase 1 clinical trial for VIR-5525, an EGFR-targeting T-cell engager for solid tumors, triggering a $75 million milestone payment to Sanofi.

Vir Biotechnology, Inc. announced the successful election of two Class III directors and the approval of executive compensation and the independent auditor at its 2025 Annual Meeting of Stockholders.

Vir Biotechnology reports preliminary Phase 2 data for its hepatitis B treatment candidates, tobevibart and elebsiran, while streamlining the program and prioritizing its hepatitis delta efforts.

Vir Biotechnology announces its Q1 2025 financial results, highlighting progress in clinical programs and a strong cash position.

Vir Biotechnology announces its Q4 and full year 2024 financial results, highlighting progress in its clinical programs and a focus on strategic priorities.

Vir Biotechnology has announced the departure of its Chief Technology Officer and the appointment of a new Chief Technical Operations Officer.

Vir Biotechnology reports encouraging initial safety and efficacy data from Phase 1 trials of its dual-masked T-cell engagers, VIR-5818 and VIR-5500, showing tumor shrinkage and PSA declines in heavily pretreated patients.

Vir Biotechnology announced a strategic licensing agreement with Sanofi, a pipeline refocus, and its third quarter 2024 financial results, including a net loss of $213.7 million.

Vir Biotechnology has finalized an exclusive licensing agreement with Sanofi for T-cell engagers and a masking platform, while also appointing Jason O'Byrne as its new Chief Financial Officer.

Vir Biotechnology is restructuring to focus on its hepatitis programs, cutting 25% of its workforce, after reporting positive clinical trial data and securing a key licensing agreement with Sanofi.

Vir Biotechnology has secured an exclusive worldwide license from Sanofi for three clinical-stage T-cell engagers and a protease-cleavable masking platform, expanding its oncology and infectious disease pipeline.

Vir Biotechnology has received FDA Fast Track designation for its combination therapy of tobevibart and elebsiran for chronic hepatitis delta infection, following positive Phase 2 trial data.

Vir Biotechnology reports positive preliminary Phase 2 trial data for tobevibart and elebsiran, showing high virologic response and ALT normalization in hepatitis delta patients.

Vir Biotechnology held its 2024 Annual Meeting of Stockholders, electing four Class II Directors and approving executive compensation and the appointment of Ernst & Young as its independent auditor.

Vir Biotechnology announced its first quarter 2024 financial results, highlighted by progress in its hepatitis programs and a strong cash position.

Vir Biotechnology announces the resignation of its CFO and the nomination of two new independent directors to its board.

Vir Biotechnology ended its influenza program collaboration with GSK, while also reporting its fourth quarter and full year 2023 financial results, including a significant decrease in revenue compared to 2022.